Madhavi Rayapudi, MD
Infectious Disease · Cumming, GANPI 1215971668
Payments from drug & device makers
Across 399 payments — averaging $18.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Viiv Healthcare Company$1K
- AbbVie$760
- Gilead$716
- Paratek Pharmaceuticals, Inc.$712
- Cumberland Pharmaceuticals, Inc.$684
- Takeda Pharmaceuticals U.S.A., Inc.$673
- plus $3K from 23 others
What the payments were for
- Consulting fees$320%
- Food & beverage$7,42698%
- Education$1021%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Viiv Healthcare Company | 76 | $1,289 |
| AbbVie(2 entities) | 40 | $760 |
| Gilead | 32 | $716 |
| Paratek Pharmaceuticals, Inc. | 53 | $712 |
| Cumberland Pharmaceuticals, Inc. | 38 | $684 |
| Takeda Pharmaceuticals U.S.A., Inc. | 29 | $673 |
| Insmed, Inc. | 25 | $595 |
| Pfizer | 22 | $435 |
| Merck | 23 | $429 |
| La Jolla Pharmaceutical Company | 18 | $372 |
| Grifols USA, LLC | 8 | $158 |
| Melinta Therapeutics, LLC | 7 | $128 |
| CSL Behring | 3 | $82 |
| Organogenesis Inc. | 3 | $73 |
| Mimedx Group, Inc. | 4 | $72 |
| Shionogi Inc | 3 | $57 |
| Astellas Pharma US Inc | 2 | $47 |
| Tetraphase Pharmaceuticals, Inc. | 2 | $34 |
| ADMA Biomanufacturing LLC | 1 | $32 |
| Invivyd Inc | 1 | $31 |
| Convatec Inc. | 1 | $26 |
| Philips North America LLC | 1 | $25 |
| Mayne Pharma Commercial LLC | 1 | $23 |
| Dynavax Technologies Corporation | 1 | $21 |
| Advanced Respiratory, Inc | 1 | $21 |
| ETS Wound Care LLC | 1 | $20 |
| Romark Laboratories, LC | 1 | $18 |
| Access Pro Medical, LLC | 1 | $17 |
| Ferring Pharmaceuticals Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Mavyret$118
How this compares
$7,560 in reported general payments places this provider in the 70th percentile of 260 infectious disease providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| HizentraImmun Glob G(Igg)/Pro/Iga 0-50 | 13 | $114,290 |
| Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov50 | 14 | $92,613 |
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 13 | $55,164 |
| Daptomycin | 111 | $44,211 |
| Gamunex-CImmune Globul G/Gly/Iga Avg 46 | 12 | $41,054 |
| ErtapenemErtapenem Sodium | 40 | $17,240 |
| CeftriaxoneCeftriaxone Sodium | 43 | $7,246 |
| Ceftazidime | 39 | $6,889 |
| Meropenem | 19 | $4,944 |
| Vancomycin Hcl | 36 | $2,964 |
| Methenamine Hippurate | 26 | $2,058 |
| Trimethoprim | 38 | $1,613 |
| Fluconazole | 44 | $737 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 33 | $729 |
| Doxycycline Monohydrate | 22 | $723 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| CSL BehringHizentra | $82 | $114,29013 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Gammagard Liquid | $673 | $92,61314 claims |
| GileadBiktarvy | $716 | $55,16413 claims |
| Grifols USA, LLCGamunex-C | $158 | $41,05412 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 260 infectious disease providers in Georgia.
Other infectious disease in Cumming
- Mark MulliganAtlanta$4.6M
- Nadine RouphaelAtlanta$2.4M
- Leila HojatAtlanta$2.2M
- Kimberly WorkowskiAtlanta$2M
- Robin DretlerDecatur$1.8M
- Harold KatnerMacon$1.3M
- Andrew DoldDacula$1.1M
- Jeffrey StephensMacon$1M
- Jose VazquezAugusta$967K
- Cheryl NewmanAugusta$945K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.